EUVIMEDEUVIMED entdecken
Multizentrische Studie

Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies

Maria Francesca Birtolo, Rebecca Pedersini, Andrea Palermo iD, Walter Vena, Emanuela Morenghi, Giacomo Cristofolini, Barbara Presciuttini, Gaia Tabacco iD, Anda Mihaela Naciu, Stella Pigni, Marta Laganà, Federica Mazzoleni und 13 weitere

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae086 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Maria Francesca Birtolo und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele-Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Premenopause, Bone Density, Bone Density Conservation Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown.

Methods

This retrospective multicenter study included 306 premenopausal women with early BC undergoing HDTs. Bone mineral density (BMD) and morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation and then after at least 24 months.

Results

After initial assessment, bone-active drugs were prescribed in 77.5% of women (151 denosumab 60 mg/6 months, 86 bisphosphonates). After 47.0 ± 20.1 months, new VFs were found in 16 women (5.2%). Vertebral fracture risk was significantly associated with obesity (odds ratio [OR] 3.87, P = .028), family history of hip fractures or VFs (OR 3.21, P = .040], chemotherapy-induced menopause (OR 6.48, P < .001), preexisting VFs (OR 25.36, P < .001), baseline T-score less than or equal to −2.5 standard deviation (SD) at any skeletal site (OR 4.14, P = .036), and changes at lumbar and total hip BMD (OR 0.94, P = .038 and OR 0.88, P < .001, respectively). New VFs occurred more frequently in women untreated compared to those treated with bone-active drugs (14/69, 20.8% vs 2/237, 0.8%; P < .001) and the anti-fracture effectiveness remained significant after correction for BMI (OR 0.03; P < .001), family history of fractures (OR 0.03; P < .001), chemotherapy-induced menopause (OR 0.04; P < .001), and preexisting VFs (OR 0.01; P < .001).

Conclusions

Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPremenopauseBone DensityBone Density Conservation AgentsDiphosphonatesHumansFemaleRetrospective StudiesAdultMiddle AgedSpinal FracturesDenosumabOsteoporosis

Stichwörter der Autor:innen

aromatase inhibitorsbisphosphonatesbone mineral densitybreast cancerdenosumabosteoporosispremenopausal womenvertebral fractures

Substanzen

Bone Density Conservation AgentsDiphosphonatesDenosumab

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele-Milan, Italy.
  • Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano-Milan, Italy.
  • Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy.
  • Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Diabetology and Endocrinology, Humanitas Gavazzeni, 24125 Bergamo, Italy.

ORCID-Profile: Andrea Palermo, Gaia Tabacco, Nicola Napoli, Andrea Gerardo Lania, Alfredo Berruti, Gherardo Mazziotti

Zitieren

APA

Birtolo, M. F., Pedersini, R., Palermo, A., Vena, W., Morenghi, E., Cristofolini, G., Presciuttini, B., Tabacco, G., Naciu, A. M., Pigni, S., Laganà, M., Mazzoleni, F., Cosentini, D., Ciafardini, A., Pagani, M., Farina, D., Balzarini, L., Zambelli, A., Torrisi, R., …, & Mazziotti, G. (2024). Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae086

Vancouver

Birtolo MF, Pedersini R, Palermo A, Vena W, Morenghi E, Cristofolini G, et al. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae086

BibTeX
@article{Birtolo2024,
  author = {Birtolo, Maria Francesca and Pedersini, Rebecca and Palermo, Andrea and Vena, Walter and Morenghi, Emanuela and Cristofolini, Giacomo and Presciuttini, Barbara and Tabacco, Gaia and Naciu, Anda Mihaela and Pigni, Stella and Laganà, Marta and Mazzoleni, Federica and Cosentini, Deborah and Ciafardini, Antea and Pagani, Mauro and Farina, Davide and Balzarini, Luca and Zambelli, Alberto and Torrisi, Rosalba and Cianferotti, Luisella and Napoli, Nicola and Bossi, Antonio Carlo and Lania, Andrea Gerardo and Berruti, Alfredo and Mazziotti, Gherardo},
  title = {Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae086}
}
Kostenlos starten →